Form 4 for NEO NEOGENOMICS INC
Accepted 2022-04-04 00:00:00 ET · period of report 2022-04-01 · accession 0001077183-22-000055 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-04-04 | 2022-04-01 | NEO | Sholehvar David | Pres, Clinical Services | A - Grant | $0.00 | +30.9K | 30.9K | New | $0 |
| D | 2022-04-04 | 2022-04-01 | NEO | Sholehvar David | Pres, Clinical Services | A - Grant | $0.00 | +66.4K | 66.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-01 | A | A | 30,864 | $0.00 | 30,864 | D | — | — | (F1) On April 1, 2022, Dr. Sholehvar was granted 30,864 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-04-01 | A | A | 66,372 | $0.00 | 66,372 | D | $12.15 · — to 2029-04-01 | 66,372 Common Stock | (F2) On April 1, 2022, Dr. Sholehvar was granted 66,372 stock options. These options vest ratably over the first four anniversary dates of the grant date. |